期刊文献+

雷珠单抗和PDT治疗湿性AMD的疗效比较 被引量:7

Comparison of lucentis and photodynamic therapy in the treatment of wet age-related macular degeneration
下载PDF
导出
摘要 目的:比较雷珠单抗和光动力疗法(photodynamic therapy,PDT)治疗湿性年龄相关性黄斑变性(age-related macular degeneration,AMD)的临床疗效。方法:回顾性分析23例PDT治疗的湿性AMD患者和23例予雷珠单抗玻璃体腔内注射治疗的湿性AMD患者的资料,比较两组在治疗后1,3,6mo的视力、OCT及FFA变化情况。结果:两组患者术后1,3mo视力均得到明显提高,两组在统计学意义上无显著差异,雷珠单抗组有2例(9%)患者在治疗后6mo出现视力回降现象,PDT组患者在术后3mo及术后6mo视力变化稳定。结论:雷珠单抗和PDT治疗湿性AMD,均能有效控制湿性AMD患者病情发展并能改善患者视力,两种疗法疗效的比较在短期内无统计学意义,但是术后6mo,PDT的稳定性优于雷珠单抗。 AIM: To compare the clinical curative effect with lucentis and photodynamic therapy in the disease of wet age-related macular degeneration. METHODS: A retrospective study in 23 cases with photodynamic therapy ( PDT ) , and another 23 patients who were injected lucentis.We compared the results of best corrected visual acuity, OCT and FFA after 1mo, 3mo and 6mo. RESULTS: Both groups had a great significant improvement in best corrected acuity visual at 1mo and 3mo later.The comparison between the two groups had no statistical significance.But the best corrected visual acuity in 2 patients ( 9%) of lucentis group was lower at 6mo than at 1mo and 3mo. CONCLUSION:The study showed the two methods for treating wet age -related macular degeneration were effective in short time, but the stability at 6mo of PDT group was better than lucentis group.
机构地区 金华眼科医院
出处 《国际眼科杂志》 CAS 2014年第3期438-440,共3页 International Eye Science
关键词 年龄相关性黄斑变性 雷珠单抗 光动力疗法 age -related macular degeneration lucentis photodynamic therapy
  • 相关文献

参考文献10

  • 1Souied E, Kaplan J, Coscas G, et al. Age- related macular degeneration and genetics. J Fr Ophthalmol 2001 ;24 ( 8 ) : 875 - 885 2.
  • 2Ferris FL 3rd , Fine SL, Hyman L. Age-ralated macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102( 11 ) :1640-1642 3.
  • 3Barbazetto I, Burdan A, Bressler NM,et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment: TAP and VIP report No 2. Arch Ophthalmol 2003;121:1253-1268 4.
  • 4Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crstal structure of an affinity-matrured Fab in complex with antigen. J Mol Biol 1999; 293(4) : 865-881 5.
  • 5Miller JW, Walsh AW, Sickenberg M, et al. Photodynamie therapy of experimental ehoroidal neovaseulafisation in age- related maeular degeneration. Eye 2000 ; 14 : 155 6.
  • 6TAP and VIP, Treatment of Age- related Maeular Degeneration with Photodynamie Therapy Study Group, Verteporfin In Photodynamie Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual aeuty change with and without verteporfin therap for ehoroidal neovasuclarizaiton secondary to age-realted maeular degeneration: TAP and VIP report no 1. Am J Ophthalmol 2003 ;126:407-418 7.
  • 7Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 ;355 (14) : 1419-1431 8.
  • 8Brown DM, Kaiser PK, Miehcls M, et al. ANCHOR study group. Ranibizumab versus verteporfin for neovascular age- related macular degeneration. N Engl J Med 2006 ;355 ( 14 ) : 1432-1444 9.
  • 9Nguyen QD, Shah SM, Heier JS,et al. Primary end point ( six months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009 ; 116:2175-2181 10.
  • 10Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012 ; 119 : 789-801.

同被引文献37

引证文献7

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部